Kevin Mark Slawin MD
Minimally Invasive Surgery, Surgical Oncology
Biotechnology Founder, Investor and Entrepreneur, Founder and Managing Partner, Rapha Capital Management LLC, Founder, Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), Founder and CEO, Eos SENOLYTIX, Inc. (https://eossenolytix.com), Founder and CEO, Deliver Therapeutics, Inc. (https://deliverthera.com), Chairman and CEO, PrintBio, Inc. (https://printbio.com)
Join to view full profile
9511 Collins Avenue#1403Bal Harbour, FL 33154
Phone+1 305-809-6920
Fax+1 305-675-3972
Dr. Slawin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kevin Slawin is a urologist based in Bal Harbour, FL, with subspecialties in minimally invasive surgery and surgical oncology. He completed his education and training at esteemed institutions such as Columbia University Vagelos College of Physicians and Surgeons, New York Presbyterian Hospital, and Baylor College of Medicine. His expertise lies in immunotherapy, urologic oncology, and robotic prostatectomy. Dr. Slawin founded the first CAR-T cell company, Bellicum Pharmaceuticals in 2004, taking it public on NASDAQ in 2014 at a $500 million market cap. He is currently founder and CEO of Eos SENOLYTIX, a biotechnology company focused on the clinical development of novel therapeutics targeting biological mechanisms associated with aging. Eos’s approach is based on the hypothesis that addressing fundamental drivers of cellular dysfunction associated with aging may improve physiological function and mitigate the progression of a broad range of age-related conditions.
Education & Training
Baylor College of MedicineFellowship, Minimally Invasive Urologic Surgery, 1992 - 1994
New York Presbyterian Hospital (Columbia Campus)Residency, Urology, 1988 - 1992
Icahn School of Medicine at Mount SinaiResidency, Surgery, 1986 - 1988
Columbia University Vagelos College of Physicians and SurgeonsClass of 1986
Certifications & Licensure
FL State Medical License 2018 - 2027
NY State Medical License 1986 - 2022
TX State Medical License 1993 - 2019
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification meridianEMR, meridianEMR, Inc., 2011, 2014
- F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology. Scott Dept. of Urology, Baylor College of Medicine, 2003
- America's Top Doctors Castle Connolly, 2009-2014
Clinical Trials
Publications & Presentations
PubMed
- 72 citationsTwo-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches.My Linh T. Duong, Matthew R. Collinson-Pautz, Eva Morschl, An Lu, Slawomir P. Szymanski
Molecular Therapy Oncolytics. 2019-03-29 - Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.Matthew R Collinson-Pautz, Wei-Chun Chang, An Lu, Mariam Khalil, Jeannette W Crisostomo
Leukemia. 2019-03-01 - Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.Matthew R Collinson-Pautz, Wei-Chun Chang, An Lu, Mariam Khalil, Jeannette W Crisostomo
Leukemia. 2019-03-01
Journal Articles
- A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-S...John P Mulhall, Eric A Klein, Kevin Slawin, Peter T Scardino, The Journal of Sexual Medicine
Press Mentions
Rapha Capital Management Launches $100M Life Science VC Fund with an Eye on Early ScienceApril 16th, 2021- AHA, Children’s Heart Foundation Award Funds to Research in Congenital Heart DefectsFebruary 13th, 2021
- Biopharmaceutical Company AsclepiX Therapeutics Raises $35 MillionJune 29th, 2020
Industry Relationships
- Board Member, 3DBio, Inc2019 - Present
- Founder and Managing Partner, Rapha Capital Management, LLC2018 - Present
- Board Member, AsclepiX Therapeutics2018 - Present
- Founder, Bellicum Pharmaceuticals, Inc.2004 - Present
External Links
- Rapha Capital Management LLChttp://raphacap.com
- LinkedInhttp://linkedin.com/in/kevinslawin
- Eos SENOLYTIX https://eossenolytix.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
